Cargando…
Ponesimod inhibits astrocyte‐mediated neuroinflammation and protects against cingulum demyelination via S1P(1)‐selective modulation
Ponesimod is a sphingosine 1‐phosphate (S1P) receptor (S1PR) modulator that was recently approved for treating relapsing forms of multiple sclerosis (MS). Three other FDA‐approved S1PR modulators for MS—fingolimod, siponimod, and ozanimod—share peripheral immunological effects via common S1P(1) inte...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740777/ https://www.ncbi.nlm.nih.gov/pubmed/34986275 http://dx.doi.org/10.1096/fj.202101531R |